Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2011-03-11

Clinical Trial Update: Ambisome and Management of Culture-negative Neutropenic Fever Unresponsive to Antibiotics [Phase 4]

View source ↗

Summary

The Phase 4 trial evaluating Ambisome for culture-negative neutropenic fever unresponsive to antibiotics was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AMBISOME (AMPHOTERICIN B)

Snippet

Sponsor: Gilead Sciences | Conditions: Febrile Neutropenia | Phase 4 | Status: TERMINATED